Overview

Transthyretin Cardiac Amyloidosis in HFpEF

Status:
Completed

Trial end date:
2020-03-31

Target enrollment:

Participant gender:

Summary

To estimate the prevalence of transthyretin cardiac amyloidosis (TTR-CA) among Heart Failure with Preserved Ejection Fraction (HFpEF) patients with increased LV wall thickness in Southeast Minnesota using 99mTc-PYP single-photon positive emission computed tomography with computed tomography (SPECT/CT).

Phase:

Early Phase 1

Details

Lead Sponsor:

Mayo Clinic

Collaborator:

Pfizer